• The following are the supplementary data related to this

  2024-12-24

  

  The following are the supplementary data related to this article. Competing interest Ethics approval and consent to participate Authors' contributions Acknowledgements The authors thank Dr. D. R. Kaplan for kind advice and materials derived from NB primary cell lines, Dr. F. D. Miller f

• MMP is the most critical protease which

  2024-12-24

  

  MMP9 is the most critical protease which is involved in the degradation of ECM. TIMP-1 is an important regulator in the synthesis and degradation of ECM [8,9]. Hepatic TIMP-1 expression significantly increases in patients with liver fibrosis [10]. Serum level of TIMP-1 expression is positively assoc

• What are the in situ effects of multi site

  2024-12-24

  

  What are the in-situ effects of multi-site CaM associations with AT1R? Kai et al. showed that synthetic peptides corresponding to residues 125–137 (rat sequence) in SMD2, 217–227 in the N-terminal side of SMD3, and 304–316 in SMD4JM inhibit to various degrees AngII-induced GTPase activity of isolate

• br Conclusions br Transparency document br Acknowledgements

  2024-12-24

  

  Conclusions Transparency document Acknowledgements This work was supported by a grant from the European Commission FP6 “Neuroprion” – Network of Excellence and Royal Veterinary College Bioveterinary science research project funding. We thank Professor Alun Williams (Cambridge University) fo

• Recent work has detailed the impact of genetic deletion

  2024-12-24

  

  Recent work has detailed the impact of genetic H2A (107-122) peptide of AMPK in the liver, revealing only minor phenotypes upon removal in mice (Boudaba et al., 2018). However, these studies very elegantly showed the potential for small molecule-mediated activation of AMPK to elicit large changes in

• AMPK is a central regulator of cell growth migration metabol

  2024-12-24

  

  AMPK is a central regulator of cell growth, migration, metabolism, autophagy, and cell polarity [20], [21], [22], [23]. It is highly conserved in eukaryotes and functions as the primary sensor of intracellular adenosine nucleotides [24]. When intracellular ATP levels decrease, AMPK is activated to g

• br Discussion Elevated blood BCAA levels are a common featur

  2024-12-24

  

  Discussion Elevated blood BCAA levels are a common feature of a developed pathophysiological state characterized by obesity and IR [4]. It has been suggested that this profile is part of a panel of biomarkers able to predict the onset of more severe complications like diabetes in humans [14]. In

• The complex role of the human intestinal microbiota is emerg

  2024-12-24

  

  The complex role of the human intestinal microbiota is emerging and its functions has been elucidated when considering energy metabolism, nutrient digestion, vitamin synthesis, epithelial defenses and immune responses [34]. The colon is responsible for salvage of energy and possibly nitrogen from ca

• Table reports the results for the categorical

  2024-12-24

  

  Table 3 reports the results for the categorical coding of diagnosis. The categorical coding is less hypothesis driven than the continuous coding because it allows for nonlinear interactions that are driven by only two groups (CN → MCI stable, CN → MCI progressor, and CN → AD). That said, this analys

• The beneficial treatment with several statins have been

  2024-12-24

  

  The beneficial treatment with several statins have been evaluated in AD patients (Kivipelto et al., 2005), with controversial results. It has been suggested that statins slow cognitive decline in mild to moderate AD (Miida et al., 2005). Treatment with atorvastatin, combined with other medications,

• Targeting the BCR is the

  2024-12-23

  

  Targeting the BCR is the ideal strategy to identify the antigen reactive B cells. However, there is concern that B cells could be activated when BCR are bound and cross-linked by antigens, a possibility that is obviously negative for the treatment of autoimmune disease. Proby et al. (2000) tried to

• br Funding br Introduction l Dihydroxyphenylalanine l DOPA i

  2024-12-23

  

  Funding Introduction l-3,4-Dihydroxyphenylalanine (l-DOPA) is the gold-standard treatment for the motor symptoms of Parkinson's disease (PD); however, its chronic use induces severe motor complications that eventually limit its long-term efficacy (Bastide et al., 2015). The most disabling side

• br Current limitations and future directions

  2024-12-23

  

  Current limitations and future directions There are several limitations associated with PET imaging of aromatase using carbon-11 labeled aromatase inhibitors. Due to the very short half-life of carbon 11 (20min), PET studies with currently available, validated tracers can only be performed in me

• Aminoglutethimide first generation aromatase inhibitor has b

  2024-12-23

  

  Aminoglutethimide, first generation aromatase inhibitor, has been tried as an antiepileptic drug in combination with other standard drugs (Aguilar et al., 1961). Letrozole is a third generation reversible non-steroidal aromatase inhibitor, approved by US-FDA, for the treatment of postmenopausal wome

• The first evidence in supporting the

  2024-12-23

  

  The first evidence in supporting the hypothesis that MAS receptors mediate the effects elicited by AT1 antagonists was provided by Iwai et al. (2012). The authors found that AT1 receptors triggers neointima formation after polyethylene-cuff placement around mouse femoral artery by reducing local ACE

14391 records 36/960 page Previous Next First page 上5页 3637383940 下5页 Last page